Status:
COMPLETED
Antibody Response to COVID-19 Vaccines in Liver Disease Patients
Lead Sponsor:
Humanity & Health Medical Group Limited
Conditions:
Chronic Liver Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Currently the Pfizer-Biontech (mRNA), Sinovac (inactivated virus) and Astrazeneca-Oxford (adenovirus-vector) COVID-19 vaccines are available for vaccination in HK. The American Association of Liver Di...
Eligibility Criteria
Inclusion
- Subjects with chronic liver disease (CLD) at the Humanity and Health Medical Group and eligible for the HK government vaccination programme;
- Able to understand and sign informed consent.;
- Underlying CLD- defined as patients with chronic hepatitis B or C infections, liver cirrhosis, metabolic associated liver disease, hepatocellular carcinoma, alcoholic liver disease, autoimmune hepatitis, hemochrombtosis.
Exclusion
- Patients contraindicated for the COVID -19 Vaccination Program due to uncontrolled co-morbitities;
- Past allergies to other vaccines;
- Pregnant subjects.
Key Trial Info
Start Date :
May 21 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2023
Estimated Enrollment :
232 Patients enrolled
Trial Details
Trial ID
NCT04775069
Start Date
May 21 2021
End Date
September 30 2023
Last Update
October 4 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Humanity & Health Medical Group Limited
Hong Kong, Hong Kong